Sandbox endocarditis: Difference between revisions
No edit summary |
|||
Line 634: | Line 634: | ||
|- | |- | ||
| style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Vancomycin]] 40 mg/kg per 24 h IV in 2-3 equally divided doses x ≥6 wks'''''<BR>''PLUS''<BR> ▸'''''[[Rifampin]] 20 mg/kg per 24 h IV/PO in 3 equally divided doses x ≥6 wks'''''<BR>''PLUS''<BR>▸ '''''[[Gentamicin]] 1 mg/kg q8h IV/IM x 2 Wks''''' | | style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Vancomycin]] 40 mg/kg per 24 h IV in 2-3 equally divided doses x ≥6 wks'''''<BR>''PLUS''<BR> ▸'''''[[Rifampin]] 20 mg/kg per 24 h IV/PO in 3 equally divided doses x ≥6 wks'''''<BR>''PLUS''<BR>▸ '''''[[Gentamicin]] 1 mg/kg q8h IV/IM x 2 Wks''''' | ||
|- | |||
|} | |||
|} | |||
|} | |||
==HACEK Organisms== | |||
{| | |||
| valign=top | | |||
<div class="mw-customtoggle-table27" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 70px; line-height: 30px; width: 250px; background: #4479BA;"> | |||
<font color="#FFF"> | |||
▸ '''Therapy for Both Native and Prosthetic Valve Endocarditis Caused by HACEK Microorganisms''' | |||
</font> | |||
</div> | |||
|valign=top | | |||
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table27" style="background: #FFFFFF;" | |||
| valign=top | | |||
{| style="float: left; cellpadding=0; cellspacing= 0; width: 600px;" | |||
! style="height: 50px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Therapy for Both Native and Prosthetic Valve Endocarditis Caused by HACEK Microorganisms}} | |||
|- | |||
! style="padding: 0 5px; font-size: 95%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Adult dose}}'' | |||
|- | |||
| style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ceftriaxone|Ceftriaxone sodium]] † 2 g/24 h IV/IM in 1 dose x 4 weeks''''' | |||
|- | |||
|style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ''OR'' | |||
|- | |||
| style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ampicillin sulbactam|Ampicillin- sulbactam]] ‡ 12 g/24 h IV in 4 equally divided doses x 4 weeks''''' | |||
|- | |||
|style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ''OR'' | |||
|- | |||
| style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ciprofloxacin]] ‡¶ 500 mg q12h PO or 400 mg q12h IV x 4 weeks''''' | |||
|- | |||
! style="padding: 0 5px; font-size: 95%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Pediatric dose}}'' | |||
|- | |||
| style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ceftriaxone]] 100 mg/kg per 24 h IV/IM once daily''''' | |||
|- | |||
|style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ''OR'' | |||
|- | |||
|style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸'''''[[Ampicillin sulbactam|Ampicillin- sulbactam]] 300 mg/kg per 24 h IV divided into 4 or 6 equally divided doses''''' | |||
|- | |||
|style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ''OR'' | |||
|- | |||
|style="font-size: 95%; padding: 0 5px; background: #DCDCDC" align=left | ▸'''''[[Ciprofloxacin]] 10-15 mg/kg q12h IV/PO ''''' | |||
|- | |||
| | |||
*HACEK: Haemophilus parainfluenzae, H aphrophilus, Actinobacillus actinomycetemcomitans, Cardiobacterium hominis, Eikenella corrodens, and Kingella kingae. | |||
:† Patients should be informed that IM injection of ceftriaxone is painful. | |||
:‡ Dosage recommended for patients with normal renal function. | |||
:¶ Fluoroquinolones are highly active in vitro against HACEK microorganisms. Published data on use of fluoroquinolone therapy for endocarditis caused by HACEK are minimal. | |||
|- | |- | ||
|} | |} | ||
|} | |} | ||
|} | |} |
Revision as of 20:41, 5 March 2014
Streptococci
▸ Click on the following categories to expand treatment regimens.
Native Valve Endocarditis Caused by Viridans Group Streptococci and Streptococcus bovis ▸ Viridans Group Streptococci and Streptococcus bovis Highly Penicillin-Susceptible ▸ Viridans Group Streptococci and Streptococcus bovis Relatively Penicillin Resistant (MIC >0.12 μg/mL- ≤ 0.5 μg/mL) Prosthetic Valves Endocarditis Caused by Viridans Group Streptococci and Streptococcus Bovis ▸ Viridans Group Streptococci and Streptococcus Bovis Penicillin-Susceptible Strain (MIC ≤ 0.12 μg/mL) ▸ Viridans Group Streptococci and Streptococcus Bovis Penicillin Relatively or Fully Resistant Strain (MIC >0.12 μg/mL) ▸ Viridans Group Streptococci and Streptococcus bovis Relatively Penicillin-Resistant Streptococci (MIC 0.2–0.5 µg/ml) ▸ Relatively Penicillin-Resistant Streptococci (MIC > 0.5 µg/ml) ▸ Unable to tolerate Penicillin or Ceftriaxone |
|
|
|
|
|
|
|
Enterococci
Endocarditis Caused by Enterococci ▸ Enterococci Strains Susceptible to Penicillin, Gentamicin, and Vancomycin ▸ Enterococci Strains Susceptible to Penicillin, Streptomycin, and Vancomycin and Resistant to Gentamicin ▸ Enterococci Strains Resistant to Penicillin and Susceptible to Aminoglycoside and Vancomycin ▸ Enterococci Strains Resistant to Penicillin, Aminoglycoside, and Vancomycin |
|
|
|
|
Staphylococci
Native Valve Endocarditis caused by Staphylococci in the Absence of Prosthetic Material ▸ Staphylococci (Methicillin Susceptible) ▸ Staphylococci (Methicillin-resistant) with Penicillin G Anaphylactoid Hypersensitivity Prosthetic Valves Endocarditis or Other Prosthetic Material Caused by Staphylococci ▸ Oxacillin-Susceptible Strains ▸ Oxacillin-Resistant Strains |
|
|
|
|
HACEK Organisms
▸ Therapy for Both Native and Prosthetic Valve Endocarditis Caused by HACEK Microorganisms |
|